StockNews.com Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy

StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research report report published on Tuesday morning.

Several other brokerages also recently weighed in on COLL. Needham & Company LLC restated a hold rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Jefferies Financial Group upgraded Collegium Pharmaceutical from a hold rating to a buy rating and lifted their price target for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. Piper Sandler reiterated a neutral rating and issued a $37.00 price target (down from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Truist Financial lifted their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a buy rating in a research note on Friday, August 9th. Finally, HC Wainwright upgraded Collegium Pharmaceutical from a neutral rating to a buy rating and set a $47.00 price target for the company in a research note on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $42.00.

Collegium Pharmaceutical Stock Up 0.6 %

Shares of Collegium Pharmaceutical stock opened at $36.26 on Tuesday. The business has a 50-day moving average of $33.82 and a 200-day moving average of $35.00. The company has a debt-to-equity ratio of 1.98, a current ratio of 1.21 and a quick ratio of 1.14. The company has a market capitalization of $1.19 billion, a PE ratio of 15.11 and a beta of 0.93. Collegium Pharmaceutical has a 1-year low of $20.95 and a 1-year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company’s revenue was up 7.2% on a year-over-year basis. During the same period last year, the firm earned $1.13 earnings per share. As a group, equities analysts forecast that Collegium Pharmaceutical will post 5.73 EPS for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the transaction, the chief financial officer now directly owns 130,845 shares in the company, valued at $4,476,207.45. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 3.98% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Hedge funds have recently made changes to their positions in the business. Gladius Capital Management LP bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at approximately $32,000. Principal Securities Inc. bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $40,000. nVerses Capital LLC raised its holdings in shares of Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares during the last quarter. Sheaff Brock Investment Advisors LLC bought a new stake in shares of Collegium Pharmaceutical during the first quarter valued at approximately $204,000. Finally, Assetmark Inc. raised its holdings in shares of Collegium Pharmaceutical by 25.5% during the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after buying an additional 1,108 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.